SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Orphan drugs: legal aspects, current situation
1 references·2 citing·13 second hop
Orphan drugs: legal aspects, current situation (2002)Orphan drugs: legal aspects, current situ…Rare diseases and orphan drugs (2006)Rare diseases and orphan drugsWhy orphan drug coverage reimbursement decision-making needs patient and public involvement (2015)Why orphan drug coverage reim…Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007 (2010)Global Spending on Orphan Dru…A Ladder Of Citizen Participation (1969)Public Participation Methods: A Framework for Evaluation (2000)A Typology of Public Engagement Mechanisms (2005)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)National Institute for Clinical Excellence and its value judgments (2004)Why rare diseases are an important medical and social issue (2008)Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe (2010)Drugs for Rare Diseases: Influence of Orphan Designation Status on Price (2011)Unintended effects of orphan product designation for rare neurological diseases (2012)Orphan drugs and the NHS: should we value rarity? (2005)Exploring emerging technologies using metaphors – A study of orphan drugs and pharmacogenomics (2008)Orphan drug development is not taking off (2009)Orphan drugs: the regulatory environment (2012)
this work references cited by second hop

References

  • 2006Rare diseases and orphan drugs144 cited

Cited by

  • 2010Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 200757 cited
  • 2015Why orphan drug coverage reimbursement decision-making needs patient and public involvement48 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work